JP Morgan analyst Brian Essex maintains Okta (NASDAQ:OKTA) with a Overweight and raises the price target from $90 to $95.
Apple Watch Versions Minus Blood Oxygen Feature To Go On Sale In US As Cupertino Devises Way To Sidestep Looming Ban
Apple Inc. modifies its latest Apple Watch models for the U.S. market by removing the blood oxygen feature, in response to a pending ban due to an intellectual property dispute with Masimo Corporation.